We present a retrospective investigation of the role of genomics in the prediction of central versus marginal disease progression patterns for @entity463 ( @entity463 ). Between August 2000 and May 2010, 41 @entity1 with @entity463 and gene expression and methylation data available were treated with radiotherapy with or without concurrent temozolomide. Location of disease progression was categorized as within the high dose (60  Gy) or low dose (46  Gy) volume. Samples were grouped into previously described TCGA genomic groupings: Mesenchymal (m), classical (c), proneural (pn), and neural (n); and were also classified by @entity8724 -Methylation status and G-Cimp methylation phenotype. Genomic groupings and methylation status were investigated as a possible predictor of disease progression in the high dose region, progression in the low dose region, and time to progression. Based on TCGA category there was no difference in @entity3012 (p  =  0.26), 60  Gy progression ( @entity6841 : 71  %, N: 60  %, M: 89  %, C: 83  %, p  =  0.19), 46  Gy progression ( @entity6841 : 57  %, N: 40  %, M: 61  %,C: 50  %, p  =  0.8) or time to progression ( @entity6841 : 9  months, N:15  months, M: 9  months, C: 7  months, p  =  0.58). @entity8724 methylation predicted for improved @entity3012 (median 25 vs. 13  months, p  =  0.01), improved DFS (median 13 vs. 8  months, p  =  0.007) and decreased 60  Gy (p  =  0.003) and 46  Gy (p  =  0.006) progression. There was a cohort of @entity8724 methylated @entity1 with late marginal disease progression (4/22 @entity1 , 18  %). TCGA groups demonstrated no difference in survival or progression patterns. @entity8724 methylation predicted for a statistically significant decrease in in-field and marginal disease progression. There was a cohort of @entity8724 methylated @entity1 with late marginal progression. Validations of these findings would have implications that could affect radiation field size.

Genomic predictors of patterns of progression in XXXX and possible influences on radiation field design.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6841 :: ('MESH:C565820', 'Disease') :: ['PN'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity8724 :: ('4255', 'Gene') :: ['MGMT'] @entity463 :: ('MESH:D005909', 'Disease') :: ['GBM', 'glioblastoma']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']
